Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML.
Resource Type
Academic Journal
Authors
Uy GL; Division of Oncology, Washington University School of Medicine, St. Louis, MO.; Newell LF; Knight Cancer Institute, Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR.; Lin TL; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.; Goldberg SL; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.; Wieduwilt MJ; Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK.; Ryan RJ; Department of Biostatistics, Jazz Pharmaceuticals, Philadelphia, PA.; Faderl S; Department of Clinical Development, Jazz Pharmaceuticals, Palo Alto, CA; and.; Lancet JE; Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
Source
Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE